drugset
drugset / Trial / NCT04501250

Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method

NCT04501250 ↗

Completed 52 enrolled Geropharm
RandomizedCrossoverDouble-blindBasic science

Summary

Сomparative pharmacokinetic study of Rinsulin® NPH, suspension for subcutaneous administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, suspension for subcutaneous administration, 100 IU/ml (Lilly France, France) using the euglycemic hyperinsulinemic clamp.

Timeline

Start
2017-10-23
Primary completion
2018-01-01
Completion
2018-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 0.4 iu/kg Subcutaneous
Subject Rinsulin NPH Unknown 0.4 iu/kg Subcutaneous

Indications

No indication recorded.